Literature DB >> 9874494

Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium.

Y Ishiwata1, S Yokochi, H Hashimoto, F Ninomiya, T Suzuki.   

Abstract

Propagermanium (3-oxygermylpropionic acid polymer) is an organic germanium compound that activates the immune system. In this study, we investigated the action of propagermanium on T-cell-mediated murine hepatic injury induced by concanavalin A (Con A). Oral administration of propagermanium inhibited the development of liver injury about 10 h after ConA injection. Histological analysis demonstrated that propagermanium attenuated the extent of liver damage compared with controls, reducing infiltration by leucocytes, especially CD11b-positive cells. Infiltration by CD4-positive cells was not affected. Tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma are crucial for the development of hepatitis in this model. Propagermanium treatment induced significant inhibition of subsequent TNF-alpha production about 10 h after Con A injection, without affecting IFN-gamma, interleukin (IL)-10, IL-4 and IL-12 production. This effect on TNF-production coincided with the inhibition of aminotransferase activity late in the progression of Con A-induced liver injury. These facts suggest that this compound affects the macrophages (Mphi) function in the liver sinusoid. Therefore, Mphi were cultured with liver sinusoidal endothelial cells (SEC) and the effect of propagermanium on TNF-alpha production in the presence of IFN-gamma was determined. TNF-alpha production was reduced significantly in the coculture of Mphi and SEC when Mphi was treated with propagermanium. These results might explain the mechanisms by which propagermanium inhibits Con-A-induced liver injury. That is, propagermanium improves hepatitis through mechanisms including the reduced production of TNF-alpha, without modification of Th1- and Th2-cell function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874494     DOI: 10.1046/j.1365-3083.1998.00434.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Protective effects of cyclosporine A on T-cell dependent ConA-induced liver injury in Kunming mice.

Authors:  X L Zhang; Q Z Quan; Z Q Sun; Y J Wang; X L Jiang; D Wang; W B Li
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder.

Authors:  Kazuhiro Kataoka; Yutaka Kono; Masanobu Sugimoto; Yasuhiro Furuichi; Masayoshi Shichiri; Yujiro Tanaka
Journal:  Exp Ther Med       Date:  2010-09-29       Impact factor: 2.447

3.  Blockade of CCR2 ameliorates progressive fibrosis in kidney.

Authors:  Kiyoki Kitagawa; Takashi Wada; Kengo Furuichi; Hiroyuki Hashimoto; Yoshiro Ishiwata; Masahide Asano; Motohiro Takeya; William A Kuziel; Kouji Matsushima; Naofumi Mukaida; Hitoshi Yokoyama
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 4.  Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.

Authors:  Kanae Yumimoto; Shigeaki Sugiyama; Koshi Mimori; Keiichi I Nakayama
Journal:  Cancer Sci       Date:  2019-06-10       Impact factor: 6.716

Review 5.  The role of chemokines in hepatitis C virus-mediated liver disease.

Authors:  Anette Brass; Erwin Daniel Brenndörfer
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.